Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer
US11324822B2 · kind B2 · utility
3Cited by
0References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 18, 2016 |
| Grant date | May 10, 2022 |
| Priority date | — |
| Expiry date | Mar 18, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.